Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the first quarter of 2013 and provided an update on development programs. 

The Company reported total revenues of $440 million in the first quarter of 2013, compared to $232 million in the first quarter of 2012.  Total revenues include EYLEA U.S. net product sales of $314 million in the first quarter of 2013, compared to $124 million in the first quarter of 2012.  The Company reported non-GAAP net income of $201 million, or $1.78 per diluted share, in the first quarter of 2013, compared to $40 million, or $0.37 per diluted share, in the first quarter of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the Company's convertible senior notes, and non-cash income taxes.  The Company reported GAAP net income of $99 million, or $0.90 per diluted share, in the first quarter of 2013, compared to $12 million, or $0.11 per diluted share, in the first quarter of 2012. 

"The first quarter of 2013 was a productive quarter where we delivered sustained revenue and earnings growth," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "EYLEA sales in the U.S. continue to enjoy strong growth and we are raising our estimate of full year U.S. EYLEA net sales to $1.25 to $1.325 billion in 2013.  The ex-U.S. launch of EYLEA by our partner, Bayer HealthCare, is also going very well and resulted in a positive contribution to our earnings this quarter.  Our broad, late-stage pipeline is making progress.  We expect our first data from the alirocumab Phase 3 program for reducing LDL cholesterol in the second half of 2013.  We reported positive data with our IL-4R inhibitor, dupilumab, in atopic dermatitis and additional data for dupilumab are expected in allergic ast
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 ... Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen ... Royal Philips (NYSE: PHG, AEX: ... Röntgenkongress 2015 (ECR) bekannt, der vom 4. bis ... An den Ständen Nr. 102 and 110 ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
(Date:3/3/2015)... /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences company ... for advanced microarray diagnostics, today announced it has ... Management team. In his capacity as CFO he ... a development stage to a commercially successful company ... capital market strategy and to secure funding to ...
(Date:3/3/2015)... 2015  Regenicin, Inc. (OTC Bulletin Board: ... of and commercialization of regenerative cell therapies to restore ... that it has received the final payment to conclude ... (OTC Bulletin Board: AMBS ). ... final payments due to Regenicin in the amount of ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3
... Most school districts still are not teaching skills needed for ... are behind in understanding that we are way beyond the ... teaching the classical three Rs. I am not talking about ... and routine. All of these add up to regimentation, which ...
... Wis. - Cray Inc. , the Seattle-based ... here, has been awarded a $250 million agreement from ... to develop what the company calls a revolutionary ... Chippewa Falls operation remains unclear. , ,The agreement, which ...
... Wisconsin has a chance to attract a major federal laboratory. It ... Health Center was established in Madison, and nearly 100 years ... University of Michigan as the site for the ... the world's knowledge of wildlife diseases and forests - as well ...
Cached Biology Technology:Rote education fails the Information Age 2Rote education fails the Information Age 3Rote education fails the Information Age 4Cray signs $250M deal to develop supercomputer 2National Bio and Agro Defense fits Wisconsin 2National Bio and Agro Defense fits Wisconsin 3National Bio and Agro Defense fits Wisconsin 4
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... likely to happen - you being in a car wreck or ... are greater killers win a free trip to the beach. It's ... of being in a wreck are far greater than being a ... sciences who has studied sharks for years. , Worldwide, about one ...
... Providing safer shellfish is the goal of Agricultural Research ... which pathogenic bacteria enter shellfish. , In the United ... of concern: V. vulnificus and V. parahaemolyticus. These bacteria ... water temperatures are warm, and can lead to serious ...
... sleep-deprived months with your newborn were tough, pity the ... the June 30 edition of the peer-reviewed journal Nature, ... dolphins and killer whales that is unique from other ... a day during their first month. , The mother ...
Cached Biology News:Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research 2Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development 2
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: